Sunday, February 1, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Almonty Industries Approaches All-Time High on Operational Milestones

Dieter Jaworski by Dieter Jaworski
February 1, 2026
in Analysis, Commodities, Emerging Markets, Industrial
0
Almonty Stock
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Shares of Almonty Industries are trading near record levels, driven not by short-term headlines but by significant operational progress. The company’s flagship Sangdong tungsten mine in South Korea entered commercial production in December 2025, shifting investor focus squarely onto production targets and supply chain dynamics. This development is particularly timely, given the tungsten market has tightened considerably.

The critical question for the industry is whether Sangdong can become a cornerstone for non-Chinese supply. The answer hinges on the mine’s ramp-up to full capacity.

Strategic Shift as Production Commences

The transition from construction to active production in late 2025 marks a fundamental change for Almonty. Company leadership has stated that at full capacity, Sangdong could supply approximately 40% of the global non-Chinese demand within its market segment.

This strategic position is bolstered by regulatory tailwinds. A ban on Chinese tungsten imports for U.S. defense applications is scheduled for 2027, increasing pressure on Western supply chains to secure alternative sources. The mine’s launch coincides with a favorable pricing environment; tungsten prices surged by over 160% in 2025, according to market data, providing a strong backdrop for new production.

Key Data Points:
* Sangdong Status: Commercial production began December 2025
* Tungsten Price: Increased more than 160% in 2025
* Recent Share Price (Frankfurt Close): €9.75
* Market Capitalization: Approximately €2.66 billion

Should investors sell immediately? Or is it worth buying Almonty?

Capital Management and Insider Activity

Recent corporate filings show activity on two fronts. In January, director Thomas Joerg Gutschlag sold 89,630 shares valued at around CAD 1.2 million, reducing his holding by roughly 7.5%.

Separately, the company issued a “Cleansing Statement” yesterday regarding the allotment of 370,303 new common shares. This move is part of ongoing capital management as Almonty scales its operations across multiple jurisdictions.

Forward Outlook: North American Expansion and Upcoming Report

While Sangdong ramps up, Almonty is advancing its North American expansion. The company’s Gantung Browns Lake project in Montana is currently targeted to begin production in the second half of 2026.

In the near term, market attention will center on how swiftly Sangdong’s output translates into revenue. Investors await the next financial report, currently expected on March 27, 2026, for the first concrete figures from the new producing asset.

Ad

Almonty Stock: Buy or Sell?! New Almonty Analysis from February 1 delivers the answer:

The latest Almonty figures speak for themselves: Urgent action needed for Almonty investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 1.

Almonty: Buy or sell? Read more here...

Tags: Almonty
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Intellia Therapeutics Stock
Analysis

Intellia Therapeutics Clears Key Regulatory Obstacle for Gene Therapy Trial

February 1, 2026
Synopsys Stock
AI & Quantum Computing

Synopsys Stock: The Integration Challenge Takes Center Stage

February 1, 2026
Rocket Lab USA Stock
Industrial

Rocket Lab Advances Neutron Rocket Development Amid Shifting Market Conditions

February 1, 2026
Next Post
Alphabet Stock

Alphabet's Valuation Boosted by Autonomous Driving Ambitions

Diginex Stock

Diginex Pivots to Sustainability Tech with New Leadership

Rocket Lab USA Stock

Rocket Lab Advances Neutron Rocket Development Amid Shifting Market Conditions

Recommended

Healthcare cloud based

Consistent Confidence in UnitedHealth Group RBC Capital Analyst Reiterates Outperform Rating and 596 Price Target

2 years ago
DB Gold Double Long ETN Stock

Leveraged Gold ETN Surges Amid Precious Metal Boom

4 months ago
Uranium Energy Stock

Uranium Energy Stock Gains Strategic Advantage with U.S. Policy Shift

3 months ago
Home Construction Stock Exchange

Vulcan Materials Co Reveals Financial Outlook for Fiscal Year 2024

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Synopsys Stock: The Integration Challenge Takes Center Stage

Rocket Lab Advances Neutron Rocket Development Amid Shifting Market Conditions

Diginex Pivots to Sustainability Tech with New Leadership

Alphabet’s Valuation Boosted by Autonomous Driving Ambitions

Almonty Industries Approaches All-Time High on Operational Milestones

Fiserv Deepens AI Integration Through Expanded ServiceNow Alliance

Trending

Intellia Therapeutics Stock
Analysis

Intellia Therapeutics Clears Key Regulatory Obstacle for Gene Therapy Trial

by Andreas Sommer
February 1, 2026
0

A significant regulatory roadblock has been removed for Intellia Therapeutics. The U.S. Food and Drug Administration (FDA)...

Cadence Design Stock

Cadence Design Shares Face Critical Earnings Test

February 1, 2026
Warner Bros. Discovery (A) Stock

Acquisition Battle Intensifies for Warner Bros. Discovery

February 1, 2026
Synopsys Stock

Synopsys Stock: The Integration Challenge Takes Center Stage

February 1, 2026
Rocket Lab USA Stock

Rocket Lab Advances Neutron Rocket Development Amid Shifting Market Conditions

February 1, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Intellia Therapeutics Clears Key Regulatory Obstacle for Gene Therapy Trial
  • Cadence Design Shares Face Critical Earnings Test
  • Acquisition Battle Intensifies for Warner Bros. Discovery

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com